The Administration of Xultophy for Diabetic Patients on Hemodialysis

Tomoki Fujikawa(Tokushima Hospital), Shinnichi Waka(Tokushima Hospital), Takafumi Kawata(Tokushima Hospital), Kyoko Wada(Tokushima Hospital), Hiroshi Bando(National Institute of Advanced Industrial Science and Technology), Miyuki Narutaki(Tokushima Hospital), Hiroshi Kakutani(Tokushima Hospital), Yukio Kato(Kanazawa University), Kenji Ishikura(Kitasato University), Yuka Shirai(Tokushima Hospital), Shinya Matsuzaki(Tokushima Hospital), Masami Yamamoto(Fujita Health University)
Unknown
October 20, 2020
10.36502/2020/droa.6172
Cited by 3

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135